Nuclera Launches GPCR-Focused Nanodisc Panel to Streamline Membrane Protein Production

Enables expression of active GPCRs in 48 hours, supports screening to scale-up on eProtein Discovery

Mar. 30, 2026 at 11:53am

Got story updates? Submit your updates here. ›

A bold, abstract painting in earthy tones of green, brown, and blue, featuring sweeping geometric shapes and precise botanical spirals that conceptually represent the complex structure and interactions of G-Protein Coupled Receptors.Nuclera's nanodisc panel streamlines the production of active G-Protein Coupled Receptors, unlocking new possibilities for drug discovery.Boston Today

Nuclera, a biotechnology company enabling rapid access to high-quality proteins, has announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). The nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of challenging therapeutic targets, GPCRs, producing active proteins in 48 hours.

Why it matters

Despite one third of FDA-approved drugs acting on GPCRs, obtaining purified, stable, functional GPCRs remains a critical bottleneck in pharmacology and drug discovery. Nuclera's nanodisc panel aims to address this challenge by providing a streamlined approach to GPCR production, which could accelerate drug discovery workflows.

The details

Nuclera's nanodisc panel includes a GPCR screen kit and scale-up reagents, comprising 8 nanodisc combinations with 2 membrane scaffold proteins (MSPs) and 4 lipid compositions. This allows researchers to rapidly and cost-effectively express active GPCRs, minimizing variability associated with traditional approaches to membrane protein production. The preassembled nanodiscs target the specific charge, fluidity and/or cholesterol requirements for GPCR activity and yield.

  • Nuclera released its membrane protein workflow in 2025.
  • Nuclera announced the launch of its GPCR-focused nanodisc panel on March 30, 2026.

The players

Nuclera

A biotechnology company enabling rapid access to high-quality proteins.

Dr Audrey Dubourg

Product Manager at Nuclera.

Dr Michael Chen

CEO and co-founder of Nuclera.

Got photos? Submit your photos here. ›

What they’re saying

“Since releasing our membrane protein workflow in 2025, we have identified a huge potential in the market to support GPCR protein scientists. Our eProtein Discovery™ nanodisc panel empowers researchers to explore physiologically relevant environments validated for solubility, insertion and stabilization of membrane proteins. Compared to traditional approaches, these are capable of increasing protein yield whilst maintaining functionality, creating a fast-track route to purified, active GPCRs.”

— Dr Audrey Dubourg, Product Manager

“The release of our GPCR nanodisc panel addresses the pressure scientists face to rapidly produce functional membrane proteins. Integrated with eProtein Discovery, this capability equips researchers with a powerful approach to increase success rates in expressing active GPCRs.”

— Dr Michael Chen, CEO and co-founder

What’s next

Nuclera plans to continue expanding its nanodisc panel and eProtein Discovery capabilities to further streamline membrane protein production and drug discovery workflows.

The takeaway

Nuclera's GPCR-focused nanodisc panel represents a significant advancement in the field of membrane protein research, providing a fast-track solution to producing active GPCRs and addressing a critical bottleneck in pharmacology and drug discovery.